Pit5 Music News Cache

www.pit5.com saves this page so readers can view old news that may not still be availible elsewhere.
This is a saved page of Omega Pharma "buy," target price raised (New Ratings)
This is a copy we made of the page on 12-Apr-2006.
The original page may or may not still be availible and pictures and text may have changed since then.
Click Here to view the original page at the original website.

Omega Pharma "buy," target price raised | newratings.com

Watchlist | About | Home


	Search Analyst News

Most viewed:

Vodafone Up; Verizon Report Dismissed 04/12/06

Microsoft to challenge Google Scholar 04/12/06

Isoft Higher; "Dead Cat Bounce" - Analyst 04/12/06

more...

Europe | Omega Pharma quote - chart - all headlines - analyst actions - add to watchlist

Stuttgart: OPM.STU at 1.58PM ET €50.05

+0.82 (+1.67%)

Omega Pharma "buy," target price raised

Monday, April 03, 2006 4:52:00 AM ET
ING Financial Markets

LONDON, April 3 (newratings.com) - Analyst Luc Struelens of ING Financial Markets reiterates his "buy" rating on Omega Pharma (OPM.ETR). The target price has been raised from €54 to €60.

In a research note published this morning, the analyst mentions that the company is likely to post 1Q06 sales growth of 6.2%, primarily driven by the Omega Europe and Omega Belgium divisions. Omega Pharma is expected to witness EPS CAGR of 11.8% during 2005-2008, the analyst adds.

Omega Pharma | detailed quote - chart - all headlines - add to watchlist

03/20/06	Degroof Raises Omega Pharma Target, EPS
03/17/06	Bank Degroof To Upgrade Omega Pharma
03/15/06	Omega Pharma "buy," target price raised	ING Financial Markets

Copyright © 2002 - 2006 newratings.com, a Joint Venture of
New Ratings Inc. and aktiencheck.de AG | Legal | Licensing

Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using Standard&Poor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.

All content copyright newratings.com. All rights reserved. Republication or redistribution strictly prohibited without the prior written consent of newratings.com. In no event shall newratings.com be held liable for this or any other content, or for any actions taken in reliance thereon. newratings.com makes no warranties, either express or implied, as to the fitness of the content for any particular purpose.